Browsing Tag
Thomas Burns
3 posts
Glaukos (NYSE: GKOS) targets $1bn in sales. Can Epioxa offset iDose risk?
Glaukos shares surged in after-hours trading after the company raised its 2026 revenue forecast and introduced a US$1 billion sales target for 2027. But the ambitious outlook depends on a successful Epioxa rollout and continued demand for iDose TR, whose Medicare coverage remains under review.
Glaukos at ASCRS 2026: Epioxa commercial launch and the growing case for interventional eye care
Glaukos presents Epioxa and iDose TR data at ASCRS 2026. Full coverage of the keratoconus launch, glaucoma pipeline, Q4 results, and 2026 revenue guidance for NYSE: GKOS.
Glaukos closes Avedro acquisition to expand corneal health franchise
Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its…